相关实验视频

Updated: Jan 17, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

下一代Bcl-2抑制剂:设计和评估具有抗癌潜力的印度三衍生物

Ahmed M Almehdi^1,2, Samar Damiati¹, Ihsan A Shehadi^1,2

¹College of Sciences, Department of Chemistry, University of Sharjah, P.O. Box 27272, Sharjah, UAE.

|September 18, 2025

概括

针对Bcl-2蛋白家族的新型化合物显示出强大的抗癌活性. 一个有前途的Bcl-2抑制剂R23有效诱导细胞亡和细胞循环停止,突出其治疗潜力.

科学领域:

生物化学生物化学
分子生物学分子生物学
药用化学医学化学

背景情况:

Bcl-2蛋白家族调节细胞亡,是癌症治疗的关键标.
开发有效的抑制剂对于破坏癌细胞中的抗亡机制至关重要.

研究的目的:

设计,合成和评估新的Bcl-2抑制剂.
为了识别破坏抗亡和亲亡蛋白之间的相互作用的化合物.
评估新的抑制剂的抗癌潜力和作用机制.

主要方法:

新型化合物的化学合成.
在人癌细胞系中使用IC50度对抗癌活性进行体外评估.
测试ELISA结合测试以确定抑制功效.
细胞亡和细胞周期分析.
计算研究包括水图和分子动力学模拟.

主要成果:

化合物R4,R14,R17和R23表现出强烈的抗癌活性,具有亚微分子IC50值.
在ELISA试验中,R4,R14和R23表现出强大的结合亲和力 (IC50:0.25-0.63μM).
R23显著诱导了亡和G1细胞周期停止.
计算分析表明R23与Bcl-2的良好相互作用和稳定性.

结论:

新型Bcl-2抑制剂,特别是R23,在癌症治疗中显示出显著的治疗潜力.
由于R23能够诱导细胞亡和细胞循环停止,再加上对BCL-2的强烈结合,使其成为一个有前途的药物候选者.
需要对R23作为BCL-2抑制剂进行进一步的研究.

关键词:

这是一种抗癌药物.灭症 (apoptosis) 是一种死亡的过程.这是一种bcl-2抑制剂.印度 (Indole) 是一种制剂.三醇三醇的使用方法

更多相关视频

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...